Results 141 to 150 of about 11,874 (152)

Natalizumab treatment perturbs memory‐ and marginal zone‐like B‐cell homing in secondary lymphoid organs in multiple sclerosis

European Journal of Immunology, 2012
Raquel Planas, Ilijas Jelcic, Sven Schippling   +2 more
exaly  

Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases

Multiple Sclerosis Journal, 2013
Carlo Pozzilli, Lucia Moiola, Alessandra Lugaresi   +2 more
exaly  

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

Multiple Sclerosis Journal, 2016
Damiano Baroncini, A Ghezzi, Bruno Colombo   +2 more
exaly  

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab

Multiple Sclerosis Journal, 2018
Patricia Mulero, Cristina Auger, Elena Fonseca   +2 more
exaly  

Progressive multifocal leukoencephalopathy and natalizumab

Journal of Neurology, 2011
Kerstin Hellwig, Ralf Gold, Hellwig Kerstin   +2 more
exaly  

Natalizumab

Reactions Weekly, 2017
openaire   +1 more source

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

Multiple Sclerosis Journal, 2018
Birgit I Witte, Mike P Wattjes, Theo Rispens   +2 more
exaly  

Natalizumab

Reactions Weekly, 2018
  +4 more sources

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

Multiple Sclerosis Journal, 2011
Clemens Warnke, Thomas Dehmel, Marcel Andree   +2 more
exaly  

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

Multiple Sclerosis Journal, 2015
Clemens Warnke, Mark Stettner, Thomas Dehmel   +2 more
exaly